Abstract: A milled carbon fiber reinforced polymer having increased abrasion resistive characteristics. The reinforced polymer comprises a base resin selected from the group consisting of polyolefins and polyamides. The base resin is combined with an amount of milled carbon fibers and further may be combined with polytetrafluoroethylene. The resulting composite materials have excellent friction and wear characteristics and are useful in the production of injection molded parts. The molded parts have a high impact strength, exhibit dimensional stability, are abrasion resistive, and are static dissipative, with the composite materials having particular utility as support fixtures for semiconductors during certain processing operations.
Type:
Grant
Filed:
April 23, 1996
Date of Patent:
November 11, 1997
Assignee:
Empak, Inc.
Inventors:
Brian Massengale, Paul Schauer, Charles Dahle, Barry Gregerson, Bonnie Bachman, Thomas Oesterle
Abstract: A novel gene, huntingtin, is described, encoding huntingtin protein, recombinant vectors and hosts capable of expressing huntingtin. Methods for the diagnosis and treatment of Huntington's disease are also provided.
Type:
Grant
Filed:
May 20, 1994
Date of Patent:
November 11, 1997
Assignee:
The General Hospital Corporation
Inventors:
Marcy E. MacDonald, Christine M. Ambrose, Mabel P. Duyao, James F. Gusella
Abstract: There is provided an advantageous process for production of EPA by a gene recombinant technique wherein genes coding for biosynthesis enzymes for eicosapentaenoic acid (EPA) useful as pharmaceuticals, agrochemicals, foods, feeds or the like is obtained from microorganisms.EPA is produced by obtaining genes coding for eicosapentaenoic acid (EPA) biosynthesis enzymes, constructing a plasmid by joining the genes to a vector, transforming E. coli with the plasmid, and culturing the transformed E. coli.
Abstract: Process for producing an extracellular heme protein in increased yields, the process comprising culturing an apoprotein producing microorganism in a fermentation medium containing heme or a heme-containing material under conditions permitting the production of active, recombined heme protein, and recovering the resulting heme protein from the culture medium.
Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.
Abstract: A desired protein having the formula:A--B--C--Pwhereina) A is Lys or Arg, and B and C are arbitrary amino acids, orb) A is an arbitrary amino acid different from Pro, Lys and Arg, and B and/or C is Pro,is produced from a biosynthetically formed amino acid extended protein having the formula:X--A--B--C--Pwherein A, B, C and P are as defined above, and X is an amino acid sequence with an even number of amino acids, of which the first one, seen from the N-terminal end, is different from Lys and Arg, all other uneven amino acids are different from Pro, Lys and Arg, and all even amino acids are different from Pro, by reaction with the enzyme dipeptidyl aminopeptidase (DAP I). The desired protein is obtained in a pure state. Thus, e.g. hGH without content of Met-hGH may be produced by the process.
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
October 21, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Henrik Dalb.o slashed.ge, John Pedersen, Thorkild Christensen, J.o slashed.rli Winnie Ringsted, Torben Ehlern Jessen
Abstract: Mechanically stable, self-inverting water-in-oil polymer emulsions for use in industrial water treatment, waste water treatment, sludge conditioning, ore dressing, papermaking, secondary and tertiary oil recovery containing carboxylated ethoxylated phenols and alcohols are provided.
Abstract: The present invention provides a polypeptide represented by the following amino acid sequence: ##STR1## wherein n is 0 or 1 and X represents Pro Ala Gly Thr Arg Ala Asn Asn Thr Leu Leu Asp Ser Arg Gly Trp Gly Thr Leu Leu Ser Arg Ser Arg Ala Gly or a fragment thereof (n=0: SEQ ID NO:1, n=1: SEQ ID NO:2), a recombinant DNA coding for the polypeptide, a vector containing the recombinant DNA, the preparation of a transformant carrying the vector, and the production of the polypeptide with the transformant. The use of this peptide in pharmaceutical compositions is also provided.
Type:
Grant
Filed:
October 31, 1995
Date of Patent:
October 21, 1997
Assignees:
Takeda Chemical Industries, Inc., President of National Cancer Center
Inventors:
Koji Yoshimura, Kaori Ishimaru, Koichi Igarashi, Masaaki Terada
Abstract: There are described, cleaning compositions comprising proteolytic enzymes having enhanced thermal and/or alkaline stability. Particularly, the compositions comprise a Bacillus sp. subtilisin having enhanced thermal stability and alkaline stability. The composition may be useful for any cleaning application such as laundry cleaning, household cleaning (dishcare, hard surface cleaning) or industrial cleaning.
Type:
Grant
Filed:
April 28, 1995
Date of Patent:
October 14, 1997
Assignee:
Genencor International, Inc.
Inventors:
Stanley E. Mainzer, Pushkaraj L. Lad, Brian F. Schmidt
Abstract: The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native anthrax PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided.
Type:
Grant
Filed:
June 25, 1993
Date of Patent:
October 14, 1997
Assignee:
The Government of the United States as represented by the Secretary of the Department of Health and Human Services
Inventors:
Stephen H. Leppla, Kurt R. Klimpel, Naveen Arora, Yogendra Singh, Peter J. Nichols
Abstract: A method of reducing immunoglobulin E responses associated with certain immune disorders is provided. The method comprises administering an effective amount of an antagonist to human interleukin-4. Preferably, the antagonist is a blocking monoclonal antibody specific for human interleukin-4, or a fragment or binding composition derived therefrom.
Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
Abstract: The present invention provides an analogue of human .alpha.-1-antichymotrypsin wherein the amino acid at position 358 is selected from the group consisting of isoleucine, valine, alanine, aspattic acid, threonine, and glutamic acid.
Type:
Grant
Filed:
March 31, 1994
Date of Patent:
October 7, 1997
Assignee:
Trustees of the University of Pennsylvania
Inventors:
Barry S. Cooperman, Harvey Rubin, Norman Schechter, Zhi Mei Wang
Abstract: Synthetic biopolymers can be prepared using recombinant DNA technology or chemical synthetic methods which have properties similar to naturally occuring gelatin or collagen. These materials comprise one or more polypeptides having the peptide sequence represented by the formulaeI:{?(Gly Pro Gln)(Gly Pro Glu).sub.4 !.sub.2 }.sub.nII:Gly Pro Glu{?(Gly Pro Gln)(Gly Pro Glu).sub.4 !.sub.2 }.sub.nIII:Gly Pro Xaa.sub.1 Gly Leu Xaa.sub.2 Gly Pro Arg Gly Pro Pro Gly Ala Set Gly Ala Pro Gly Pro Glu Gly Phe Gln GlywhereinXaa.sub.1 and Xaa.sub.2 are independently the amino acids identified as Met, Ile, His, Lys, Asn, Tyr or Gln, and n is 1 to 25.
Type:
Grant
Filed:
February 3, 1995
Date of Patent:
September 23, 1997
Assignee:
Eastman Kodak Company
Inventors:
Shane Crawford Weber, John Alan McElver
Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 23, 1997
Assignee:
Sloan-Kettering Institute
Inventors:
Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsm, Malcolm A. S. Moore
Abstract: A purified insulin-like protein (ILP) isolated from Saccharomyces cerevisiae is disclosed. The ILP has a molecular weight of approximately 6.4 kilodaltons and the amino acid sequence of the 22 amino terminal residues of the protein has been determined. Computer-assisted molecular graphics analysis of ILP illustrates the similarity of the sequenced portion to vertebrate insulin A-chains.
Abstract: Methods and compositions are disclosed for producing human somatomedin carrier protein-like polypeptides. Human somatomedin carrier protein-like polypeptides, which bind somatomedins, are produced using recombinant technology. Also disclosed are methods for making complexes of human somatomedin carrier protein-like polypeptides and somatomedins.
Type:
Grant
Filed:
May 19, 1995
Date of Patent:
September 23, 1997
Assignee:
Celtrix Pharmaceuticals, Inc.
Inventors:
Emerald Martin Spencer, Carol Talkington-Verser
Abstract: A method for producing protein from DNA in a static reaction in which DNA, ribonucleotide triphosphates, magnesium and a RNA polymerase are mixed and incubated during which RNA is transcribed from the DNA and the resulting solution is added to a eukaryotic cell-free extract containing magnesium so that the RNA produced during the incubating step translates into protein and so that further transcription of the DNA is coupled to translation of the resulting RNA into protein.
Abstract: Doxorubicin resistance can be conferred on a host by transforming the host with a recombinant vector comprising a DNA having the configuration of restriction sites shown in FIGS. 1 or 2 of the accompanying drawings or a restriction fragment derived therefrom containing a gene coding for doxorubicin resistance.